Evia Bio

Minneapolis, United States Founded: 2021 • Age: 5 yrs
Non-DMSO cryopreservation technology is provided for cell therapy supply chains.

About Evia Bio

Evia Bio is a Healthcare company based in Minneapolis (United States) founded in 2021 by Allison Hubel. Non-DMSO cryopreservation technology is provided for cell therapy supply chains. Evia Bio has raised $5.45 million across 1 funding round. Its chief executive, as recorded, is Christiaan Engstrom. Evia Bio offers products and services including CryoGAP, CryoCustom Development, Non-DMSO, and CryoEducation. Its focus areas include Life Sciences, Life Sciences Platforms and Tools, Instruments and Preservation. Its competitors include Stirling Ultracold, Upkara and Montana Instruments; 2 of its 3 listed competitors have raised funding.

Company details

Evia Bio was founded in 2021 and is based in Minneapolis, United States. Cryopreservation technology is supplied for the cell therapy sector, with operations centered on non-DMSO solutions. Cell integrity is stabilized and protected during freezing and supply chain handling. Services address challenges in cell therapy logistics, supporting preservation processes across the industry.

  • Headquarters Minneapolis, United States
  • Founders Allison Hubel
  • Sectors
    Healthcare
  • Website eviabio.com
  • Social LinkedIn
Key Metrics
  • Total Equity Funding
    $5.45M (USD)

    in 1 rounds

  • Latest Funding Round
    $5.45M (USD), Series A

    Sep 2026

Products & Services of Evia Bio

Evia Bio offers a comprehensive portfolio of products and services, including CryoGAP, CryoCustom Development, Non-DMSO, and CryoEducation.

CryoGAP
Risk Assessment

Service for inspecting and evaluating cryopreservation protocols

CryoCustom Development
Custom Services

Tailored solutions to enhance cell performance in therapy

Non-DMSO
Cryoprotectant Platform

AI-driven non-toxic platform for cell preservation

CryoEducation
Training Services

Webinars and workshops on cryopreservation best practices

Funding Insights of Evia Bio

Evia Bio has successfully raised a total of $5.45M through 1 strategic funding round. The most recent funding activity was a Series A round of $5.45 million completed in September 2026. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

  • Total Funding $5.45M
  • Total Rounds 1
  • Last Round Series A β€” $5.45M
  • First Round $5.45M

    (Sep 2026)

All 1 funding rounds of Evia Bio with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.

DateAmountTransaction NameValuationLead InvestorsInvestors
Sep 2026$5.45MSeries A––
–

People of Evia Bio

4 people are tracked at Evia Bio (4 in leadership).

NameRoleGroup
Allison Hubel
FounderLeadership
Christiaan Engstrom
CEOLeadership
Allison Hubel, PhD
Founder and CSOLeadership
Rachel Leon
Director Of OperationsLeadership
Premium access

Complete people profiles for Evia Bio

Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.

  • Full employee list
  • Team structure
  • Board tenure
  • Professional contacts

Verified entity values are shown only after access is granted.

Timeline of Evia Bio

2 dated milestones of Evia Bio across 5 years, from founding to its latest funding, stage changes and deals.

  1. Founded Evia Bio is founded.
  2. Funding First funding round of $5.5M.

Competitors of Evia Bio

Evia Bio has 3 listed competitors in our database, 2 of them funded. They include Stirling Ultracold, Upkara and Montana Instruments.

Company NameDomainFoundedHQ LocationTotal fundingEmployeesDescription
stirlingultracold.com2009Athens, United States$8.7M187
Freezers for scientific, medical, and electronics preservation are manufactured.
upkara.com2014Ann Arbor, United States$13M13
Provides freeze-free stabilization for biomolecules, enabling room-temperature storage and shipping.
montanainstruments.com2008Bozeman, United States41
Optical measurement solutions are developed for life sciences industries.
Premium access

Detailed competitors of Evia Bio

The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.

  • Full competitor set
  • Operating metrics
  • Benchmarks
  • Competitive positioning

Verified entity values are shown only after access is granted.

Top companies in Life Sciences Platforms & Tools

3 companies that operate in the same segment as Evia Bio (Life Sciences Platforms & Tools) in United States, ranked by their profile score on The Company Check.

CompanyDescriptionFoundedLocationTotal fundingRevenueEmployees
Medidata is recognized as a leading provider of SaaS solutions for clinical research.
1999New York, New York, United StatesUSD 41.5 M
AI-based solutions for health management are provided.
2015Dallas, Texas, United StatesUSD 2.8 B1,111
Real-world health data is provided for research and decisions.
2012Menlo Park, California, United StatesUSD 259.16 M
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track β€” from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • βœ“
    Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • βœ“
    Full access to every database India & global coverage, advanced filters and rich profile details
  • βœ“
    Always-on access from your team account Single premium plan for everything you see on the portal

Related news about Evia Bio

Premium access

Complete news archive for Evia Bio

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Evia Bio

Evia Bio was founded in 2021 and raised its 1st funding round 5 years after it was founded.

Evia Bio is headquartered in Minneapolis, United States. It is registered at Minneapolis, Minnesota, United States.

Christiaan Engstrom is the CEO of Evia Bio, as recorded in our data.

Evia Bio is a funded company, having raised a total of $5.45M across 1 funding round to date. The company's 1st funding round was a Series A of $5.45M, raised on Sep 2026.

Evia Bio was founded in 2021 and is based in Minneapolis, United States. Cryopreservation technology is supplied for the cell therapy sector, with operations centered on non-DMSO solutions. Cell integrity is stabilized and protected during freezing and supply chain handling. Services address challenges in cell therapy logistics, supporting preservation processes across the industry.

Evia Bio's top competitors include Stirling Ultracold, Montana Instruments and Upkara.

Evia Bio offers CryoGAP, CryoCustom Development, Non-DMSO, and CryoEducation.

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available